BenevolentAI
ben is being developed to address key unmet needs in the treatment of atopic dermatitis atopic dermatitis treatment paradigm ben development is targeting against both itch and in with potential disease modifying effects improved safety pro suitable for chronic use with no irritancy on application positioning potential to displace ineffective and poorly tolerated second line treatment for chronic use in adults and potential use in a subset of line patients where rapid itch resolution is key and in the severe patient population as an adjunct treatment option | BenevolentAI
Company
Deck Type
Deck date
September 2022
Slide
50 of 74
Similar slides by BenevolentAI
Investor Presentation
October 2022
Related slides by other companies
Results
October 2022
Investor Presentation
October 2022
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io